2024年5月1日-10日，全球医药市场共签署了18笔资产授权和合作协议。其中，中国医药市场共达成4笔交易，包括3笔出海交易和1笔国内交易。其中有2笔交易均与GLP-1激动剂相关，先为达生物与韩国HK inno.N Corpora就Ecnoglutide的韩国权益达成许可和合作协议，以及通化东宝与北京质肽生物就司美格鲁肽仿制药达成商业化授权及合作协议。
全球范围内，共签署了14项资产授权和合作协议。其中金额最大的一笔是Poseida Therapeutics与Astellas达成的首付5000万美元、总额5.5亿美元的授权交易。另一笔值得注意的交易是Flagship Pioneering与Novo Nordisk就MIMIC平台达成的总额6亿美元的合作交易。
From May 1 to May 10, a total of 18 licensing and cooperation deals were signed globally. Specifically, in the China Biotech Industry, there were 3 out-licensing deals and 1 domestic deal, while two of them are related with GLP-1 agonists. Sciwind Biosciences and inno.N signed a cooperation and licensing deal for Ecnoglutide. And, domestically, QL Biopharm and Tonghua DongbaoPharmaceutical sealed a licensing and cooperation agreement for SemaglutideBiosimilar.
Globally, a total of 14 licensing and cooperation deals were signed. The licensing and cooperation deal between Poseida Therapeutics and Astellas topped this week with a total deal amount of $550 million and an upfront payment of $50 million. Another deal highlight of the week is the cooperation deal between Metaphore Biotechnologies, Flagship Pioneering, and Novo Nordisk for MIMIC platform with the total deal amount of $600 million.
2b. Global section
3. M&A Deals
4. Top Deals of the year 2024
雅法资本成立于2013年，作为新型投资和投行咨询机构，致力于中国及海外生物医药项目的投资、融资服务、产品引进和资产孵化等。雅法在生物医药跨境授权及并购业务领域过往三年交易数量排名第一。旗下雅法基金联合药企进行资产投资和并购，雅法全球医疗专注于医药产品跨境及国内授权交易。基于雅法在全球广泛的人脉与资源网络，在过去十年成功推进了大量的海外项目进入中国市场并协助多个中国产品完成海外授权。雅法拥有经验丰富的全球交易团队，覆盖美国、日本 、欧洲等全球主要医药创新区域。核心合伙人均为华尔街资深投行人士或具有跨国药企经历，为客户交易提供强力支持。雅法总部位于上海，在伦敦、洛杉矶、东京、米兰、剑桥等地均设有分部。
Founded in 2013, YAFO Capital is a Shanghai based boutique investment and advisory firm, with professional team in our China, U.S., and London offices. Partnering with Pharmaceutical companies, YAFO Fund mainly invests in global assets. YAFO Life Sciences is a leading advisory boutique focused on asset transactions. YAFO has built a strong proven track record and closed dozens of in-licensing and out-licensing transactions with global pharma and biotech companies. YAFO has been ranked as the No. 1 advisor for China cross border licensing transactions in the past three years. For more information, please visit www.yafocapital.com
Event Name: ACCESS CHINA Partnering Forum @BIO
Date & Time: June 3-20, 2024
Venue: San Diego & Online
Content: Keynote Speeches, Panel Discussion, Virtual Roadshows, Dinner Reception, 1X1 meetings
Scale: Expected 1000 participants Online, 150 participants onsite; 100 company roadshows
Participants: Pharma/Biotech senior management and BDs.
